CA2908365C - Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using linalool - Google Patents

Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using linalool Download PDF

Info

Publication number
CA2908365C
CA2908365C CA2908365A CA2908365A CA2908365C CA 2908365 C CA2908365 C CA 2908365C CA 2908365 A CA2908365 A CA 2908365A CA 2908365 A CA2908365 A CA 2908365A CA 2908365 C CA2908365 C CA 2908365C
Authority
CA
Canada
Prior art keywords
composition
linalool
group
brain trauma
food product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2908365A
Other languages
English (en)
French (fr)
Other versions
CA2908365A1 (en
Inventor
Susana CAMACHO
Stephanie Michlig Gonzalez
Johannes Le Coutre
Henry Markram
Maurizio PEZZOLI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Societe des Produits Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA filed Critical Societe des Produits Nestle SA
Publication of CA2908365A1 publication Critical patent/CA2908365A1/en
Application granted granted Critical
Publication of CA2908365C publication Critical patent/CA2908365C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2908365A 2013-05-24 2014-05-23 Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using linalool Active CA2908365C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361827232P 2013-05-24 2013-05-24
US61/827,232 2013-05-24
PCT/EP2014/060637 WO2014187945A1 (en) 2013-05-24 2014-05-23 Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using menthol, linalool and/or icilin

Publications (2)

Publication Number Publication Date
CA2908365A1 CA2908365A1 (en) 2014-11-27
CA2908365C true CA2908365C (en) 2023-02-28

Family

ID=50819728

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2908365A Active CA2908365C (en) 2013-05-24 2014-05-23 Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using linalool

Country Status (10)

Country Link
US (2) US20160166570A1 (enExample)
EP (1) EP3003292B1 (enExample)
JP (2) JP2016520588A (enExample)
CN (1) CN105228601A (enExample)
AU (2) AU2014270341A1 (enExample)
BR (1) BR112015026484A2 (enExample)
CA (1) CA2908365C (enExample)
ES (1) ES2721922T3 (enExample)
TR (1) TR201906539T4 (enExample)
WO (1) WO2014187945A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520588A (ja) * 2013-05-24 2016-07-14 ネステク ソシエテ アノニム メントール、リナロール及び／又はイシリンを用いる脳外傷及び卒中からの非炎症性ニューロン傷害の処置又は予防
JP7641973B2 (ja) * 2020-03-24 2025-03-07 中国▲医▼薬大学 神経変性疾患及び脳卒中を改善する外用組成物の調製に用いられるメントールの用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL164828A0 (en) * 2002-04-25 2005-12-18 Brainsgate Ltd Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head
JP4742204B2 (ja) * 2005-01-21 2011-08-10 財団法人ヒューマンサイエンス振興財団 脂肪細胞分化制御剤
JP2007291069A (ja) * 2006-03-31 2007-11-08 Daiichi Sankyo Healthcare Co Ltd 抗酸化剤および／または消炎鎮痛剤組成物
GB0615136D0 (en) * 2006-07-29 2006-09-06 Univ Edinburgh Induction of analgesia in neuropathic pain
KR20090085237A (ko) * 2008-02-04 2009-08-07 김병문 천연 진주가루를 함유한 뇌질환 예방 및 치료용 한약조성물
WO2011006073A1 (en) * 2009-07-10 2011-01-13 President And Fellows Of Harvard College Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
KR20120103317A (ko) * 2011-03-10 2012-09-19 한국생명공학연구원 아실 코에이:콜레스테롤 아실트랜스퍼라제 저해활성을 갖는 고수씨 추출물 또는 이로부터 분리된 리나로올을 포함하는 조성물
US9585875B2 (en) * 2011-12-19 2017-03-07 Dompé Farmaceutici S.P.A. TRPM8 antagonists
CN102512634A (zh) * 2011-12-26 2012-06-27 神威药业（张家口）有限公司 复方麝香软胶囊及其制备方法
WO2013168090A1 (en) * 2012-05-07 2013-11-14 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Researc Organization (Aro) (Volcanii Center). Geranium oil and constituents thereof for treatment of neurodegenerative diseases
JP2016520588A (ja) * 2013-05-24 2016-07-14 ネステク ソシエテ アノニム メントール、リナロール及び／又はイシリンを用いる脳外傷及び卒中からの非炎症性ニューロン傷害の処置又は予防

Also Published As

Publication number Publication date
WO2014187945A1 (en) 2014-11-27
CN105228601A (zh) 2016-01-06
JP2016520588A (ja) 2016-07-14
AU2014270341A1 (en) 2015-10-08
JP2020011985A (ja) 2020-01-23
EP3003292B1 (en) 2019-03-20
AU2019222781B2 (en) 2021-05-13
CA2908365A1 (en) 2014-11-27
BR112015026484A2 (pt) 2017-07-25
TR201906539T4 (tr) 2019-05-21
US10799502B2 (en) 2020-10-13
ES2721922T3 (es) 2019-08-06
EP3003292A1 (en) 2016-04-13
US20170189403A1 (en) 2017-07-06
US20160166570A1 (en) 2016-06-16
AU2019222781A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
US20160108004A1 (en) Treatment or prevention of neurodegenerative disorders using menthol, linalool and/or icilin
AU2019222781B2 (en) Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using Menthol, Linalool and/or Icilin
US20160108005A1 (en) Treatment or prevention of depression using menthol and/or icilin
US10159653B2 (en) Methods and compositions for increasing energy expenditure using cinnamaldehyde
US11241433B2 (en) Treatment or prevention of autism disorders using menthol, linalool and/or icilin

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190423

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250402

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250402